- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- FDA approves first generic version of Genentech chemotherapy pill
- Reports: Mich. bill would allow marijuana sales in pharmacies
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
REDWOOD CITY, Calif. — Drug maker AP Pharma has appointed two new executives and may receive financing of up to $4.5 million, the company said Monday.
AP announced the appointment of John Whelan as president, CEO and director, and Michael Adam as SVP and COO.
It also entered into agreements with investors, including Tang Capital Partners, for a private placement of up to $4.5 million in convertible notes. Upon the closing, which is expected to happen Friday, the company will receive $1.5 million. AP plans to put the money toward winning Food and Drug Administration approval for AP530 (granisetron), a drug for treating chemotherapy-induced nausea and vomiting.